New
York
|
14-1702188
|
(State
or other jurisdiction of
|
(I.R.S.
Employer
|
incorporation
or organization)
|
Identification
No.)
|
122
Smith Road, Kinderhook, New York
|
12106
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Large
accelerated filer ¨
|
Accelerated
filer ¨
|
Non-accelerated
filer ¨
|
Smaller
reporting company x
|
PAGE
|
|||
PART
I – FINANCIAL INFORMATION
|
|||
Item
1.
|
Financial
Statements
|
3
|
|
Balance
Sheets as of June 30, 2008 and December 31, 2007
|
3
|
||
|
Statements
of Operations for the six months ended June 30, 2008 and June 30,
2007
|
4
|
|
Statements
of Operations for the three months ended June 30, 2008 and June 30,
2007
|
5
|
||
Statements
of Cash Flows for the six months ended June 30, 2008 and June 30,
2007
|
6
|
||
Notes
to Financial Statements
|
7
|
||
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
13
|
|
Item
3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
18
|
|
Item
4.
|
Controls
and Procedures
|
18
|
|
PART
II – OTHER INFORMATION
|
|||
Item
1.
|
Legal
Proceedings
|
18
|
|
Item
1A.
|
Risk
Factors
|
18
|
|
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
18
|
|
Item
3.
|
Defaults
Upon Senior Securities
|
18
|
|
Item
4
|
Submission
of Matters to a Vote of Security Holders
|
19
|
|
Item
5.
|
Other
Information
|
19
|
|
Item
6.
|
Exhibits
|
19
|
|
Signatures
|
20
|
June 30,
2008
|
December 31,
2007
|
||||||
(Unaudited)
|
|||||||
ASSETS
|
|||||||
Current
assets
|
|||||||
Cash
and cash equivalents
|
$
|
92,000
|
$
|
336,000
|
|||
Accounts
receivable - net of allowance for doubtful accounts of $105,000 at
both
June 30, 2008 and December 31, 2007
|
1,581,000
|
1,365,000
|
|||||
Inventory
– net of reserve for slow moving and obsolete inventory of $250,000
at
both June 30, 2008 and December 31, 2007
|
5,181,000
|
4,994,000
|
|||||
Prepaid
and other current assets
|
162,000
|
181,000
|
|||||
Total
current assets
|
7,016,000
|
6,876,000
|
|||||
Property,
plant and equipment, net
|
2,107,000
|
2,267,000
|
|||||
Other
assets
|
7,000
|
7,000
|
|||||
Total
assets
|
$
|
9,130,000
|
$
|
9,150,000
|
|||
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
|||||||
Current
liabilities
|
|||||||
Accounts
payable
|
$
|
1,646,000
|
$
|
1,403,000
|
|||
Accrued
expenses
|
402,000
|
220,000
|
|||||
Wages
payable
|
363,000
|
332,000
|
|||||
Patent
sublicense current
|
50,000
|
||||||
Line
of credit
|
566,000
|
723,000
|
|||||
Current
portion of long term debt
|
126,000
|
121,000
|
|||||
Current
portion of unearned grant
|
10,000
|
10,000
|
|||||
Total
current liabilities
|
3,113,000
|
2,859,000
|
|||||
Other
liabilities
|
102,000
|
48,000
|
|||||
Long-term
debt
|
1,043,000
|
1,107,000
|
|||||
Unearned
grant
|
40,000
|
40,000
|
|||||
Total
liabilities
|
4,298,000
|
4,054,000
|
|||||
COMMITMENTS
AND CONTINGENCIES
|
|||||||
Stockholders'
equity:
|
|||||||
Preferred
stock; par value $.01 per share; 5,000,000 shares authorized, none
issued
and outstanding at June 30, 2008 and December 31, 2007
|
|||||||
Common
stock; par value $.01 per share; 50,000,000 shares authorized; 21,744,768
issued and outstanding at both June 30, 2008 and December 31, 2007
|
217,000
|
217,000
|
|||||
Additional
paid-in capital
|
19,267,000
|
19,267,000
|
|||||
Accumulated
deficit
|
(14,652,000
|
)
|
(14,388,000
|
)
|
|||
Total
stockholders’ equity
|
4,832,000
|
5,096,000
|
|||||
Total
liabilities and stockholders’ equity
|
$
|
9,130,000
|
$
|
9,150,000
|
For The Six Months Ended
|
|||||||
June
30
|
|||||||
2008
|
2007
|
||||||
Net
sales
|
$
|
6,764,000
|
$
|
6,611,000
|
|||
Cost
of goods sold
|
3,719,000
|
3,890,000
|
|||||
Gross
profit
|
3,045,000
|
2,721,000
|
|||||
Operating
expenses:
|
|||||||
Research
and development
|
316,000
|
347,000
|
|||||
Selling
and marketing
|
1,484,000
|
1,516,000
|
|||||
General
and administrative
|
1,441,000
|
1,508,000
|
|||||
3,241,000
|
3,371,000
|
||||||
Operating
loss
|
(196,000
|
)
|
(650,000
|
)
|
|||
Other
income (expense):
|
|||||||
Interest
income
|
2,000
|
5,000
|
|||||
Interest
expense
|
(66,000
|
)
|
(65,000
|
)
|
|||
Other
expense
|
(4,000
|
)
|
|||||
(68,000
|
)
|
(60,000
|
)
|
||||
Loss
before tax
|
(264,000
|
)
|
(710,000
|
)
|
|||
Income
tax
|
|||||||
Loss
after tax
|
$
|
(264,000
|
)
|
$
|
(710,000
|
)
|
|
Basic
and diluted loss per common share
|
$
|
(0.01
|
)
|
$
|
(0.03
|
)
|
|
Weighted
average number of shares outstanding – basic & diluted
|
21,744,768
|
21,728,193
|
For The Three Months Ended
|
|||||||
June
30
|
|||||||
2008
|
2007
|
||||||
Net
sales
|
$
|
3,465,000
|
$
|
3,436,000
|
|||
Cost
of goods sold
|
1,847,000
|
1,974,000
|
|||||
Gross
profit
|
1,618,000
|
1,462,000
|
|||||
Operating
expenses:
|
|||||||
Research
and development
|
178,000
|
178,000
|
|||||
Selling
and marketing
|
716,000
|
825,000
|
|||||
General
and administrative
|
758,000
|
835,000
|
|||||
1,652,000
|
1,838,000
|
||||||
Operating
loss
|
(34,000
|
)
|
(376,000
|
)
|
|||
Other
income (expense):
|
|||||||
Interest
income
|
1,000
|
1,000
|
|||||
Interest
expense
|
(31,000
|
)
|
(38,000
|
)
|
|||
Other
expense
|
|||||||
(30,000
|
)
|
(37,000
|
)
|
||||
Loss
before tax
|
(64,000
|
)
|
(413,000
|
)
|
|||
Income
tax
|
|||||||
Loss
after tax
|
$
|
(64,000
|
)
|
$
|
(413,000
|
)
|
|
Basic
and diluted loss per common share
|
$
|
(0.00
|
)
|
$
|
(0.02
|
)
|
|
Weighted
average number of shares outstanding – basic & diluted
|
21,744,768
|
21,736,526
|
For The Six Months Ended
|
|||||||
June
|
|||||||
2008
|
2007
|
||||||
Cash
flows from operating activities:
|
|||||||
Net
loss
|
$
|
(264,000
|
)
|
$
|
(710,000
|
)
|
|
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
|||||||
Depreciation
|
181,000
|
232,000
|
|||||
Loss
on disposal of fixed assets
|
4,000
|
||||||
Non-cash
compensation expense
|
26,000
|
||||||
Changes
in:
|
|||||||
Accounts
receivable
|
(216,000
|
)
|
(242,000
|
)
|
|||
Inventory
|
(187,000
|
)
|
66,000
|
||||
Prepaid
and other current assets
|
19,000
|
(76,000
|
)
|
||||
Accounts
payable
|
243,000
|
(39,000
|
)
|
||||
Accrued
expenses
|
182,000
|
(112,000
|
)
|
||||
Other
liabilities
|
4,000
|
||||||
Wages
payable
|
31,000
|
50,000
|
|||||
Net
cash used in operating activities
|
(3,000
|
)
|
(805,000
|
)
|
|||
Cash
flows from investing activities:
|
|||||||
Purchase
of property, plant and equipment
|
(25,000
|
)
|
(564,000
|
)
|
|||
Net
cash used in investing activities
|
(25,000
|
)
|
(564,000
|
)
|
|||
Cash
flows from financing activities:
|
|||||||
Proceeds
from exercise of options
|
23,000
|
||||||
Debt
payments
|
(59,000
|
)
|
(46,000
|
)
|
|||
Proceeds
from debt financing
|
539,000
|
||||||
Proceeds
from line of credit
|
523,000
|
800,000
|
|||||
Line
of credit payments
|
(680,000
|
)
|
(228,000
|
)
|
|||
Net
cash (used in) / provided by financing activities
|
(216,000
|
)
|
1,088,000
|
||||
Net
decrease in cash and cash equivalents
|
(244,000
|
)
|
(281,000
|
)
|
|||
Cash
and cash equivalents - beginning of period
|
336,000
|
641,000
|
|||||
Cash
and cash equivalents - end of period
|
$
|
92,000
|
$
|
360,000
|
|||
Supplemental
disclosures of cash flow information
|
|||||||
Cash
paid during period for interest
|
$
|
66,000
|
$
|
65,000
|
|||
Purchase
of property, plant and equipment, financing through capital lease
|
$
|
$
16,000
|
June 30,
2008
|
June 30,
2007
|
||||||
Warrants
|
150,000
|
150,000
|
|||||
Options
|
3,768,080
|
3,968,080
|
(a)
|
Evaluation
of Disclosure Controls and
Procedures
|
Total
Shares in Attendance:
|
19,958,563
|
Outstanding
Shares as of Record Date
(April
21, 2008):
|
21,744,768
|
|||||
Director
|
For
|
Percent
of
Votes
|
Withheld
|
Percent
of
Votes
|
||||
Edmund
M. Jaskiewicz
|
18,844,394
|
94.4
|
1,114,169
|
5.6
|
||||
Daniel
W. Kollin
|
19,353,300
|
97.0
|
605,263
|
3.0
|
||||
Jean
Neff
|
|
19,354,050
|
|
97.0
|
|
604,513
|
|
3.0
|
31.1 |
Rule
13a-14(a)/15d-14(a) Certification of Chief Executive Officer
|
31.2 |
Rule
13a-14(a)/15d-14(a) Certification of Chief Financial Officer
|
32.1
|
Certification
of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350,
as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
|
32.2 |
Certification
of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350,
as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
|
AMERICAN
BIO MEDICA CORPORATION
|
|
(Registrant)
|
|
By:
|
/s/Stefan
Parker
|
Chief
Financial Officer
|
|
Executive
Vice President, Finance
|
|
Principal
Accounting Officer and duly authorized
Officer
|